0591-2245 : Mesalamine 1.2 g/1 Oral Tablet, Delayed Release


NDC: 0591-2245
Labeler: Actavis Pharma, Inc.
Product Type: Human Prescription Drug
Drug Name:  Mesalamine
Dosage Form: Oral Tablet, Delayed Release
Application #: ANDA203817
Rev. Date: 


Appearance:


Markings: WPI;2245
Shapes:  Oval
Colors:  Red
Size (mm): 21
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 0591-2245-10: 1000 TABLET, DELAYED RELEASE IN 1 BOTTLE (0591‑2245‑10)
  • 0591-2245-22: 120 TABLET, DELAYED RELEASE IN 1 BOTTLE (0591‑2245‑22)

Active Ingredients:

  • Mesalamine

Dosage Strength:

  • 1.2 g/1

Inactive Ingredients:

  • Copovidone K25-31
  • Silicon Dioxide
  • Hypromellose 2910 (6 Mpa.s)
  • Magnesium Stearate
  • Methacrylic Acid - Methyl Methacrylate Copolymer (1:1)
  • Methacrylic Acid - Methyl Methacrylate Copolymer (1:2)
  • Ferrosoferric Oxide
  • Ferric Oxide Red
  • Ferric Oxide Yellow
  • Microcrystalline Cellulose
  • Povidone K90
  • Polyethylene Glycol 400
  • Polyethylene Glycol 3350
  • Polyethylene Glycol 8000
  • Polyvinyl Alcohol, Unspecified
  • Propylene Glycol
  • Shellac
  • Sodium Starch Glycolate Type a Potato
  • Talc
  • Titanium Dioxide
  • Triethyl Citrate /

Pharmaceutical Classes:

  • Aminosalicylate [EPC]
  • Aminosalicylic Acids [CS]

Related Products:

Based on records with the same trade name.
  • 0472-1915 Mesalamine 1000 mg Rectal Suppository by Actavis Pharma, Inc.
  • 0093-5907 Mesalamine 400 mg Oral Capsule, Delayed Release by Teva Pharmaceuticals USA, Inc.
  • 0093-9224 Mesalamine 375 mg Oral Capsule, Extended Release by Teva Pharmaceuticals USA, Inc.-
  • 0378-1375 Mesalamine .375 g/1 Oral Capsule, Extended Release by Mylan Pharmaceuticals Inc.
  • 0378-7401 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Mylan Pharmaceuticals Inc.
  • 0378-9230 Mesalamine 1000 mg Rectal Suppository by Mylan Pharmaceuticals Inc.
  • 0480-7750 Mesalamine 800 mg Oral Tablet, Delayed Release by Teva Pharmaceuticals, Inc.
  • 0527-3012 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Lannett Company Inc.
  • 0781-7088 Mesalamine 1000 mg Rectal Suppository by Sandoz Inc
  • 0832-6056 Mesalamine .375 g/1 Oral Capsule, Extended Release by Upsher-smith Laboratories, LLC
  • 0904-6832 Mesalamine 800 mg Oral Tablet, Delayed Release by Major Pharmaceuticals
  • 16714-245 Mesalamine 1000 mg Rectal Suppository by Northstar Rx LLC.
  • 16714-830 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Northstar Rx LLC.
  • 21922-045 Mesalamine 4 g/60ml Rectal Suspension by Encube Ethicals Private Limited
  • 31722-005 Mesalamine 1000 mg Rectal Suppository by Camber Pharmaceuticals, Inc.
  • 31722-043 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Camber Pharmaceuticals, Inc.
  • 42291-489 Mesalamine 800 mg Oral Tablet, Delayed Release by Avkare
  • 42291-563 Mesalamine 400 mg Oral Capsule, Delayed Release by Avkare, Inc
  • 42291-564 Mesalamine 1.2 g/1 Oral Tablet, Delayed Release by Avkare, Inc
  • 43386-510 Mesalamine 4 g/60ml Rectal Enema by Gavis Pharmaceuticals, LLC
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0591-2245 QR Code

< Prev: 0591-2235Next: 0591-2258 >

Related Discussions:

Will PENTASA (mesalamine) contradict diabetes medications
I am taking PENTASA (mesalamine) 500 mg tablets daily (6 tabs daily) and I also use azoran 5 mg two tabs daily. Will it ...
Cheap Purchase of Mesalamine Enemas
I am interested in self-employment. I have Ulcerative Colitis. I need this medication to stay alive. My doctor tells me ... 1 reply
Asacol (mesalamine) delayed-release tablet
mesalamine delayed-release tablet information...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.